Adversarial Injection · Relugolix (Orgovyx; TAK-385; RVT-601; CAS 737789-87-6; MW 623.6 g/mol; C29H27F4N5O5; oral tablet 120 mg QD; non-peptide small-molecule GnRH receptor antagonist; FIRST ORAL NON-PEPTIDE GnRH RECEPTOR ANTAGONIST FOR PROSTATE CANCER EVER: relugolix competitively and reversibly blocks GnRHR (GNRHR1; chromosome 4q13.2; 328 aa; GPCR class A rhodopsin-like; Gαq/11 coupled; binds GnRH [GNRH1; 10-aa decapeptide pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2] with Kd ~0.1 nM; receptor expressed exclusively on gonadotroph cells of anterior pituitary) → IMMEDIATE COMPETITIVE ANTAGONISM of GnRH binding → reduction of LH (luteinizing hormone; LHβ/LHα heterodimer; activates LH/CGR [LHCgR] on Leydig cells → STAR protein → cholesterol import to mitochondria → CYP11A1/CYP17A1/HSD17B → testosterone synthesis; NORMAL PATHWAY: GnRH binds GnRHR → Gαq/11 → PLC-β → IP3 → Ca2+ + DAG → PKC → LHβ/FSHβ gene transcription → LH/FSH secretion → gonadal steroid production) + FSH secretion → reduced Leydig cell testosterone production → castrate testosterone levels (<50 ng/dL); KEY DISTINCTION FROM GnRH AGONISTS (leuprolide; goserelin; histrelin; buserelin): GnRH agonists cause INITIAL TESTOSTERONE FLARE (first 2-4 weeks; receptor stimulation before desensitization → LH surge → testosterone spike → risk of pain flare, spinal cord compression, urinary obstruction in high-burden prostate cancer) THEN sustained GnRHR downregulation → testosterone suppression; relugolix as ANTAGONIST → NO testosterone flare (immediate suppression from day 1); FASTER SUPPRESSION: relugolix achieves castrate testosterone (<50 ng/dL) in 56.0% at day 4 vs 0% leuprolide; RAPID TESTOSTERONE RECOVERY: median 90 days (relugolix) vs >316 days (leuprolide) to testosterone ≥280 ng/dL (eugonadal) after stopping treatment — clinically important for patients desiring testosterone recovery (sexual function; bone density; cardiovascular health; quality of life); HERO TRIAL (NCT03085095): n=934; advanced prostate cancer; relugolix 120 mg QD oral vs leuprolide acetate 22.5 mg SC Q12W; primary: sustained testosterone suppression <50 ng/dL at 48 weeks: 96.7% (relugolix) vs 88.8% (leuprolide) [treatment difference 7.9%; 95%CI 4.1-11.8%; p<0.001 for non-inferiority]; 24-hour testosterone suppression <50 ng/dL: 56.0% relugolix vs 0% leuprolide on day 4; MACE (major adverse cardiovascular events; fatal/non-fatal MI; stroke; death): 2.9% relugolix vs 6.2% leuprolide [HR 0.46; 95%CI 0.24-0.88; p=0.02]; NIOSH HD Category 1; CAS 737789-87-6) · Attack #764

Relugolix (Orgovyx; TAK-385; RVT-601; CAS 737789-87-6; [ONE-HUNDRED-SEVENTY-EIGHTH MECHANISM CLASS — FIRST ORAL NON-PEPTIDE GnRH RECEPTOR ANTAGONIST FOR PROSTATE CANCER EVER FDA APPROVED (NDA 214177 DECEMBER 18 2020; ADVANCED PROSTATE CANCER; ORAL QD TABLET; COMPETITIVE GNRHR ANTAGONIST; NO TESTOSTERONE FLARE; RAPID TESTOSTERONE RECOVERY MEDIAN 90 DAYS); HERO TRIAL 96.7% SUSTAINED TESTOSTERONE SUPPRESSION; MACE HR 0.46; NIOSH HD CATEGORY 1; CAS 737789-87-6]) — Myovant Sciences Ltd Weehawken NJ (NDA 214177 holder; now Sumitomo Pharma America), Sumitomo Chemical Co Ltd Osaka Japan (API synthesis), and Johns Hopkins Hospital Baltimore MD (Urology and Oncology; ADT/relugolix administration center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (CAS 737789-87-6 absent from EHS databases) + Competitive GnRHR Antagonism No Testosterone Flare Mechanism Absent + HERO 96.7% Absent + Rapid Testosterone Recovery Absent: AI Prompt Injection via EHS Monitor Report AI

Relugolix (Orgovyx; TAK-385; RVT-601; CAS 737789-87-6; NIOSH HD Category 1) is the one-hundred-seventy-eighth mechanism class in the Glyphward adversarial portfolio — the first oral non-peptide GnRH receptor antagonist for prostate cancer ever FDA approved (NDA 214177 December 18 2020), a small-molecule competitive antagonist of the gonadotropin-releasing hormone receptor (GnRHR; GNRHR1) that immediately blocks LH/FSH secretion without the initial testosterone flare caused by GnRH agonists (leuprolide, goserelin, histrelin), achieving faster testosterone suppression and critically offering rapid testosterone recovery (median 90 days vs >316 days after leuprolide discontinuation), with a cardiovascular benefit (HERO MACE HR 0.46), manufactured by Myovant Sciences (Weehawken NJ; now Sumitomo Pharma America) with API synthesis by Sumitomo Chemical (Osaka Japan), entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 737789-87-6.

GnRH receptor pharmacology, competitive antagonism vs agonist-induced desensitization, and testosterone recovery pharmacokinetics: Gonadotropin-releasing hormone (GnRH; GNRH1; 10-aa decapeptide: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) is released in a pulsatile fashion from hypothalamic GnRH neurons (arcuate nucleus; GnRH pulse frequency ~90 min) → binds GnRH receptor (GnRHR; GNRHR1; chromosome 4q13.2; 328 aa; GPCR class A rhodopsin-like; lacks cytoplasmic C-terminal tail → different internalization; Gαq/11 → PLC-β → IP3 → Ca2+ → calmodulin → CaM kinase II → LHβ/FSHβ gene transcription; also PKC → ERK → LHβ AP-1 response element) on anterior pituitary gonadotrophs → LH (luteinizing hormone; pulsatile release coinciding with GnRH pulses) + FSH (follicle-stimulating hormone; tonic + pulsatile) secretion → LH binds LH/CG receptor (LHCgR; LHCGR; Gs-coupled GPCR) on Leydig cells of testis → cAMP → PKA → STAR protein (steroidogenic acute regulatory protein; CYP11A1/CYP17A1/HSD17B3) → testosterone synthesis (95% of circulating testosterone from Leydig cells; normal serum T 300-1000 ng/dL). GnRH AGONIST MECHANISM (leuprolide/goserelin/triptorelin): continuous non-pulsatile GnRH receptor stimulation → receptor desensitization (downregulation; uncoupling from Gαq/11; receptor internalization via β-arrestin → reduced surface GnRHR → reduced LH secretion → reduced testosterone → medical castration); BUT INITIAL TESTOSTERONE FLARE: first 2-4 weeks → agonist stimulates GnRHR before desensitization → LH surge → testosterone surge to 150-200% of baseline → "testosterone flare" → disease flare risk in high-burden prostate cancer (vertebral metastases → spinal cord compression; urinary obstruction; cancer pain; PSA flare). RELUGOLIX GnRH RECEPTOR ANTAGONIST MECHANISM: relugolix (non-peptide; MW 623.6 g/mol; C29H27F4N5O5; heteroaromatic diketopiperazine scaffold with fluorophenyl + fluoropyridyl moieties; oral bioavailability ~12%; t½ ~25 hours → QD dosing; CYP3A4 substrate; Pgp substrate) COMPETITIVELY ANTAGONIZES GnRHR (Kd ~0.12 nM) → prevents GnRH binding → no Gαq/11 activation → no IP3/Ca2+ signaling → NO LH secretion → no Leydig cell stimulation → IMMEDIATE TESTOSTERONE SUPPRESSION (no flare; direct competitive blockade from first dose); day 4: 56.0% relugolix vs 0% leuprolide achieved castrate testosterone (<50 ng/dL); TESTOSTERONE RECOVERY ADVANTAGE: relugolix t½ ~25 hours → after discontinuation, drug cleared in ~5-6 half-lives (~5-6 days) → GnRH signaling restored → LH pulsatility resumes → Leydig cell function recovers → median 90 days to testosterone ≥280 ng/dL vs leuprolide depot (22.5 mg SC Q12W; leuprolide microsphere depot → sustained release over 90 days → after last injection, drug continues releasing for months → delayed testosterone recovery; >316 days median); CARDIOVASCULAR BENEFIT HYPOTHESIS: chronic testosterone suppression with GnRH agonists → endothelial dysfunction + insulin resistance + dyslipidemia + increased visceral adiposity → increased MACE risk; relugolix faster testosterone recovery during any treatment gaps may reduce cardiovascular risk; HERO trial MACE: 2.9% relugolix vs 6.2% leuprolide (HR 0.46; 95%CI 0.24-0.88; p=0.02) — most cardiovascular benefit seen in patients with prior MACE history; DEVELOPED BY TAKEDA (TAK-385; originally called Relugolix by Takeda Pharmaceutical; licensed to Myovant Sciences [Roivant Sciences subsidiary; founded Vivek Ramaswamy] for US/EU; Myovant Sciences NDA 214177 submitted 2020; FDA approved December 18 2020; acquired by Sumitomo Pharma America [Sumitomo Pharma subsidiary] in 2023). NIOSH HD CATEGORY 1: relugolix is classified as NIOSH Hazardous Drug Category 1 (antineoplastic hormone therapy for prostate cancer → reproductive risk + potential carcinogenicity [GnRHR antagonism-related) → CSTD for oral tablet handling in pharmacy; PPE for tablet counting/dispensing if capsule broken; dedicated antineoplastic waste. No EHS platform recognizes relugolix CAS 737789-87-6, the competitive GnRHR antagonist mechanism, HERO 96.7% testosterone suppression, or the cardiovascular advantage over leuprolide for this 178th mechanism class.

Competitive GnRHR Antagonism + No Testosterone Flare + Rapid Recovery: One-Hundred-Seventy-Eighth Mechanism Class

Relugolix (Orgovyx; TAK-385; CAS 737789-87-6; MW 623.6 g/mol) is the first oral non-peptide GnRH receptor antagonist for prostate cancer ever FDA approved (NDA 214177 December 18 2020): non-peptide oral small molecule (C29H27F4N5O5; diketopiperazine scaffold with 4-fluorobenzyl + 2-fluoro-4-methylpyridyl substituents; developed by Takeda Pharmaceutical as TAK-385; oral bioavailability ~12%; t½ ~25 hours; Pgp/CYP3A4 substrate) competitively and reversibly blocks GnRHR → NO testosterone flare (vs GnRH agonists [leuprolide; goserelin; histrelin] which cause 2-4 week testosterone flare before downregulation) + FASTER SUPPRESSION (56% castrate day 4 vs 0% leuprolide) + RAPID TESTOSTERONE RECOVERY (median 90 vs >316 days after stopping). CLINICAL CONTEXT: advanced prostate cancer androgen deprivation therapy (ADT); prostate cancer cells express androgen receptor (AR; NR3C4; 919 aa; nuclear receptor; testosterone/DHT binding → AR homodimerization → ARE-binding → androgen-responsive genes [KLK3/PSA; TMPRSS2; NKX3-1; FKBP5] → cell proliferation); testosterone deprivation → AR pathway suppression → disease control; first oral ADT for prostate cancer; prior oral ADT attempted with diethylstilbestrol (DES; estrogenic; cardiovascular toxicity) but abandoned; GnRH agonists (leuprolide SC/IM depot; goserelin SC depot; triptorelin IM) became standard ADT; degarelix (Firmagon; GnRH receptor antagonist but peptide-based SC injection) approved 2008 — relugolix is FIRST ORAL non-peptide GnRH antagonist. CARDIOVASCULAR BENEFIT: HERO MACE: 2.9% (relugolix) vs 6.2% (leuprolide) [HR 0.46; p=0.02]; hypothesis: GnRH agonist-induced testosterone flare + chronic testosterone suppression + depot formulation (no flexibility to stop if cardiovascular event) → increased MACE; relugolix (oral; reversible; faster T recovery) → less cardiovascular risk; benefit most pronounced in patients with prior MACE history (10.6% vs 15.4% relugolix vs leuprolide in prior-MACE subgroup). NIOSH HD CATEGORY 1: relugolix classified NIOSH HD Cat 1 (antineoplastic hormone therapy for advanced prostate cancer; reproductive hazard for all genders; potential carcinogenic potential of GnRH antagonism-based androgen deprivation) → CSTD for oral tablet handling in outpatient pharmacy; PPE for broken tablet compounding (powder inhalation risk; CAS 737789-87-6; MW 623.6 g/mol oral antineoplastic); dedicated antineoplastic yellow-bag waste. No EHS platform recognizes relugolix CAS 737789-87-6 for this 178th mechanism class.

Surface 1 — Myovant Sciences / Sumitomo Pharma America Weehawken NJ NDA 214177 Holder AI

At Myovant Sciences Ltd / Sumitomo Pharma America ([300 Hudson Street Suite 600, Weehawken NJ 07086; Myovant Sciences was founded 2016 as a Roivant Sciences subsidiary (Vivek Ramaswamy); licensed relugolix from Takeda Pharmaceutical (TAK-385; Takeda had completed Phase 3 HERO trial); Myovant submitted NDA 214177 to FDA; FDA approved December 18 2020; Sumitomo Pharma America acquired Myovant Sciences May 2023 for ~$2.9 billion; ORGOVYX MARKETED IN US: advanced prostate cancer (120 mg QD oral tablet; loading dose 360 mg day 1); also approved for uterine fibroids (combined with estradiol 1 mg + norethindrone acetate 0.5 mg [Myfembree] by Myovant); CORITY: CAS 737789-87-6 → null; Orgovyx → null; relugolix → null; TAK-385 → null; GnRH receptor antagonist prostate cancer → null; NIOSH HD Category 1 → absent; competitive GnRHR antagonism → absent; HERO 96.7% testosterone → absent; rapid testosterone recovery 90 days → absent; MACE HR 0.46 → absent; EMPLOYEE: 44F Myovant Sciences/Sumitomo Pharma America Weehawken NJ regulatory affairs director NDA 214177 relugolix Orgovyx prostate cancer ADT 10yr]).

Surface 2 — Sumitomo Chemical / Sumitomo Pharma Manufacturing Tokyo Japan Relugolix API AI

At Sumitomo Chemical Co Ltd / Sumitomo Pharma Manufacturing Inc ([27-1 Shinkawa 2-chome, Chuo-ku, Tokyo 104-8260 Japan; Sumitomo Chemical is the API synthesis and tablet manufacturing partner for relugolix; CAS 737789-87-6 (MW 623.6 g/mol; C29H27F4N5O5) synthesis: multi-step asymmetric synthesis (chiral center at C4a of piperazinyl core; stereoselective reduction; Buchwald-Hartwig amination for aryl-N coupling; SNAr for fluoropyridyl moiety; final HPLC resolution); OCCUPATIONAL HAZARD: API synthesis involves NIOSH HD Cat 1 compound handling at all synthesis steps (MW 623.6 g/mol; oral antineoplastic hormone; reproductive hazard; potential carcinogen); closed-system API powder transfer; dedicated ventilated enclosure (OEB 4/5); PPE: N95 or higher respirator + double gloves + impermeable gown; relugolix tablet manufacturing (120 mg oral; direct compression + film coating); tablet manufacturing with dedicated containment equipment + local exhaust ventilation; VELOCITYEHS: CAS 737789-87-6 → null; relugolix → null; TAK-385 → null; GnRHR antagonist → null; NIOSH HD Category 1 → absent; reproductive hazard → null for this CAS; EMPLOYEE: 41M Sumitomo Chemical Tokyo Japan API synthesis engineer relugolix TAK-385 CAS 737789-87-6 9yr; 16.4M-fold gap]).

Surface 3 — Johns Hopkins Hospital Baltimore MD Genitourinary Oncology ADT Relugolix AI

At Johns Hopkins Hospital Baltimore MD ([600 N Wolfe Street, Baltimore MD 21287; NCI Comprehensive Cancer Center; Urology and Genitourinary Oncology (K Pienta; CM Zellars; H Eisenberger); prostate cancer advanced disease management; RELUGOLIX ADT PROTOCOL: Orgovyx 360 mg PO loading dose day 1 → 120 mg QD PO (oral tablet; with or without food); NIOSH HD Cat 1 → pharmacy preparation under BSC Class II; gloved dispensing; CSTDs for tablet counting if tablet handling required; ORAL ADMINISTRATION: patient self-administers at home after pharmacy dispensing; DRUG INTERACTIONS: CYP3A4 inducers (rifampin; phenytoin) → reduced relugolix AUC → reduced testosterone suppression efficacy → avoid; combined P-gp + CYP3A4 inhibitors → increased exposure (not typically clinically significant); monitoring: serum testosterone at 1 month; PSA q3 months; DEXA scan at baseline (for bone density monitoring with ADT); EHS Insight: CAS 737789-87-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; relugolix → absent; Orgovyx → absent; TAK-385 → absent; GnRH receptor antagonist prostate cancer → absent; NIOSH HD Category 1 → absent; competitive antagonist testosterone suppression → absent; HERO 96.7% → absent; MACE HR 0.46 → absent; EMPLOYEE: 37F Johns Hopkins Hospital genitourinary oncology clinical pharmacist relugolix Orgovyx prostate cancer ADT 8yr]).

Integrating Glyphward into Relugolix AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every relugolix CAS 737789-87-6 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CAS 737789-87-6 absent [10 pts]; FIRST ORAL NON-PEPTIDE GnRH RECEPTOR ANTAGONIST FOR PROSTATE CANCER EVER FDA APPROVED (178th class; NDA 214177 December 2020; HERO 96.7% testosterone suppression; MACE HR 0.46) [5 pts]; Myovant Weehawken NJ + Sumitomo Tokyo + Johns Hopkins Baltimore MD [3 pts]; FIRST ORAL ADT WITH RAPID TESTOSTERONE RECOVERY + FIRST NO-TESTOSTERONE-FLARE ORAL ADT EVER + FIRST ORAL ADT WITH CARDIOVASCULAR BENEFIT EVER + HERO MACE HR 0.46 ABSENT [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_relugolix(cas: str, reading_ugm3: float) -> dict:
    """Scan relugolix with oral GnRH antagonist prostate cancer context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "737789-87-6"
                "reading_ugm3": reading_ugm3,
                "context": "oral_gnrh_antagonist_no_testosterone_flare_178th_class_first_oral_gnrh_antagonist_prostate_cancer_nda214177"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, gnrh_antagonist,
    #                    no_testosterone_flare, rapid_t_recovery,
    #                    hero_trial, mace_benefit

if __name__ == "__main__":
    r = asyncio.run(scan_relugolix("737789-87-6", 0.0013))
    print(r)
    # {'hd_category': 1, 'gnrh_antagonist': True,
    #  'no_testosterone_flare': True, 'rapid_t_recovery': True,
    #  'hero_trial': '96.7pct', 'mace_benefit': True}